An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice

Journal of Virology

Volumn 81, Issue 19, 2007, Pages 10329-10339

  White, Laura J ^a,b   Parsons, Melissa M ^a,b   Whitmore, Alan C ^a,b   Williams, Brandon M ^a,b   De Silva, Aravinda ^b   Johnston, Robert E ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; IMMUNOGLOBULIN G ANTIBODY; MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN E; VIRUS ENVELOPE PROTEIN PRM;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENGUE; ENCEPHALOMYELITIS; GENE CASSETTE; GENETIC CODE; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; VERO CELL; VIRUS PARTICLE; VIRUS STRAIN; WEANING;

ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; DENGUE VACCINES; DENGUE VIRUS; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; FEMALE; GENETIC VECTORS; IMMUNITY, MATERNALLY-ACQUIRED; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; REPLICON; VIRAL PROTEINS; VIRUS REPLICATION;

ALPHAVIRUS; DENGUE VIRUS; MUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 34648822387     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00512-07     Document Type: Article

References (71)

1. Albrecht, P., F. A. Ennis, E. J. Saltzman, and S. Krugman. 1977. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:715-718.
2. Balasuriya, U. B., H. W. Heidner, N. L. Davis, H. M. Wagner, P. J. Hullinger, J. F. Hedges, J. C. Williams, R. E. Johnston, W. David Wilson, I. K. Liu, and N. James MacLachlan. 2002. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 20:1609-1617.
3. Barouch, D. H., M. G. Pau, J. H. Custers, W. Koudstaal, S. Kostense, M. J. Havenga, D. M. Truitt, S. M. Sumida, M. G. Kishko, J. C. Arthur, B. Korioth-Schmitz, M. H. Newberg, D. A. Gorgone, M. A. Litton, D. L. Panicali, G. J. Nabel, N. L. Letvin, and J. Goudsmit. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172:6290-6297.
4. Bhamarapravati, N., and Y. Sutee. 2000. Live attenuated tetravalent dengue vaccine. Vaccine 18(Suppl. 2):44-47.
5. Blaney, J. E., Jr., A. P. Durbin, B. R. Murphy, and S. S. Whitehead. 2006. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol. 19:10-32.
6. Bot, A., and C. Bona. 2002. Genetic immunization of neonates. Microbes Infect. 4:511-520.
7. Burstyn, D. G., L. J. Baraff, M. S. Peppier, R. D. Leake, J. St Geme, Jr., and C. R. Manclark. 1983. Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect. Immun. 41:1150-1156.
8. Capozzo, A. V. E., K. Ramirez, J. M. Polo, J. Ulmer, E. M. Barry, M. M. Levine, and M. F. Pasetti. 2006. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J. Immunol. 176:5671-5681.
9. Chambers, T. J., Y. Liang, D. A. Droll, J. J. Schlesinger, A. D. Davidson, P. J. Wright, and X. Jiang. 2003. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J. Virol. 77:3655-3668.
10. Chaturvedi, U. C., R. Shrivastava, and R. Nagar. 2005. Dengue vaccines: problems and prospects. Indian J. Med. Res. 121:639-652.
11. Chen, S., M. Yu, T. Jiang, Y. Deng, C. Qin, and E. Qin. 2007. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol. 26:361-367.
12. Chulay, J., D. Burke, S. Karim, N. Russel, M. Wecker, M. Allen, G. Ferrari, and P. Gilbert. 2006. Safety and immunogenicity of an alphavirus replicon HIV gag vaccine (AVX101) in healthy HIV-uninfected adults. Abst. Aritivir. Ther. 11(Suppl. 2):196.
13. Colombage, G., R. Hall, M. Pavy, and M. Lobigs. 1998. DNA-based and alphavirus-vectored immunisation with PrM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250:151-163.
14. Davis, N. L., I. J. Caley, K. W. Brown, M. R. Betts, D. M. Irlbeck, K. M. McGrath, M. J. Connell, D. C. Montefiori, J. A. Frelinger, R. Swanstrom, P. R. Johnson, and R. E. Johnston. 2000. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. 74:371-378.
15. Durbin, A. P., R. A. Karron, W. Sun, D. W. Vaughn, M. J. Reynolds, J. R. Perreault, B. Thumar, R. Men, C. J. Lai, W. R. Elkins, R. M. Chanock, B. R. Murphy, and S. S. Whitehead. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65:405-413.
16. Eckels, K. H., and R. Putnak. 2003. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv. Virus Res. 61:395-418.
17. Edelman, R. 2005. Dengue and dengue vaccines. J. Infect. Dis. 191:650-653.
18. Fleeton, M. N., B. J. Sheahan, E. A. Gould, G. J. Atkins, and P. Liljestrom. 1999. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J. Gen. Virol. 80:1189-1198.
19. Fonseca, B. A., S. Pincus, R. E. Shope, E. Paoletti, and P. W. Mason. 1994. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 12:279-285.
20. Glezen, W. P. 2003. Effect of maternal antibodies on the infant immune response. Vaccine 21:3389-3392.
21. Gubler, D. J., and M. Meltzer. 1999. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv. Virus Res. 53:35-70.
22. Guirakhoo, F., J. Arroyo, K. V. Pugachev, C. Miller, Z. X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, and T. P. Monath. 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75:7290-7304.
23. Guzman, M. G., G. Kouri, L. Valdes, J. Bravo, M. Alvarez, S. Vazques, I. Delgado, and S. B. Halstead. 2000. Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am. J. Epidemiol. 152:793-799, 804.
24. Guzman, M. G., G. P. Kouri, J. Bravo, M. Soler, S. Vazquez, and L. Morier. 1990. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am. J. Trop. Med. Hyg. 42:179-184.
25. Halstead, S. B. 1974. Etiologies of the experimental dengue in Siler and Simmons. Am. J. Trop.Med. Hyg. 23:974-982.
26. Halstead, S. B., N. T. Lan, T. T. Myint, T. N. Shwe, A. Nisalak, S. Kalyanarooj, S. Nimmannitya, S. Soegijanto, D. W. Vaughn, and T. P. Endy. 2002. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg. Infect. Dis. 8:1474-1479.
27. Halstead, S. B., S. Nimmannitya, and S. N. Cohen. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42: 311-328.
28. Hevey, M., D. Negley, P. Pushko, J. Smith, and A. Schmaljohn. 1998. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251:28-37.
29. Holman, D. H., D. Wang, K. Raviprakash, N. U. Raja, M. Luo, J. Zhang, K. R. Porter, and J. Y. Dong. 2007. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin. Vaccine Immunol. 14:182-189.
30. Hombach, J. 2007. Scientific consultation on immunological correlates of protection induced by dengue vaccines. Vaccine 25:4130-4139.
31. Jaiswal, S., N. Khanna, and S. Swaminathan. 2003. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J. Virol. 77:12907-12913.
32. Kanra, G., S. S. Yalcin, M. Ceyhan, and K. Yurdakok. 2000. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk. J. Pediatr. 42:105-108.
33. Kliks, S. C., S. Nimmanitya, A. Nisalak, and D. S. Burke. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38:411-419.
34. Lambeth, C. R., L. J. White, R. E. Johnston, and A. M. de Silva. 2005. Flow cytometry-based assay for titrating dengue virus. J. Clin. Microbiol. 43:3267-3272.
35. MacDonald, G. H., and R. E. Johnston. 2000. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74:914-922.
36. Mackenzie, J. S., D. J. Gubler, and L. R. Petersen. 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10:S98-S109.
37. Mason, P. W., S. Pincus, M. J. Fournier, T. L. Mason, R. E. Shope, and E. Paoletti. 1991. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 180:294-305.
38. Minke, J. M., L. Siger, K. Karaca, L. Austgen, P. Gordy, R. Bowen, R. W. Renshaw, S. Loosmore, J. C. Audonnet, and B. Nordgren. 2004. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch. Virol. Suppl.18:221-230.
39. Monath, T. P., K. McCarthy, P. Bedford, C. T. Johnson, R. Nichols, S. Yoksan, R. Marchesani, M. Knauber, K. H. Wells, J. Arroyo, and F. Guirakhoo. 2002. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20:1004-1018.
40. Moran, T. P., M. Collier, K. P. McKinnon, N. L. Davis, R. E. Johnston, and J. S. Serody. 2005. A novel viral system for generating antigen-Specific T cells. J. Immunol. 175:3431-3438.
41. Nguyen, T. H., H. Y. Lei, T. L. Nguyen, Y. S. Lin, K. J. Huang, B. L. Le, C. F. Lin, T. M. Yeh, Q. H. Do, T. Q. Vu, L. C. Chen, J. H. Huang, T. M. Lam, C. C. Liu, and S. B. Halstead. 2004. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J. Infect. Dis. 189:221-232.
42. Osterhaus, A., G. van Amerongen, and R. van Binnendijk. 1998. Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine. Vaccine 16:1479-1481.
43. Pancharoen, C., and U. Thisyakorn. 2001. Dengue virus infection during infancy. Trans. R. Soc. Trop. Med. Hyg. 95:307-308.
44. Perkins, F. T., R. Yetts, and W. Gaisford. 1959. A comparison of the responses of 100 infants to primary poliomyelitis immunization with two and with three doses of vaccine. Br. Med. J. 1:1083-1086.
45. Perret, C., P. Chanthavanich, K. Pengsaa, K. Limkittikul, P. Hutajaroen, J. E. G. Bunn, and B. J. Brabin. 2005. Dengue infection during pregnancy and transplacental antibody transfer in Thai mothers. J. Infect. 51:287-293.
46. Pugachev, K. V., F. Guirakhoo, D. W. Trent, and T. P. Monath. 2003. Traditional and novel approaches to flavivirus vaccines. Int. J. Parasitol. 33:567-582.
47. Pugachev, K. V., P. W. Mason, R. E. Shope, and T. K. Frey. 1995. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology 212:587-594.
48. Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston, and J. F. Smith. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401.
49. Raviprakash, K., D. Ewing, M. Simmons, K. R. Porter, T. R. Jones, C. G. Hayes, R. Stout, and G. S. Murphy. 2003. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315:345-352.
50. Raviprakash, K., T. J. Kochel, D. Ewing, M. Simmons, I. Phillips, C. G. Hayes, and K. R. Porter. 2000. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 18:2426-2434.
51. Sanchez, V., S. Gimenez, B. Tomlinson, P. K. Chan, G. N. Thomas, R. Forrat, L. Chambonneau, F. Deauvieau, J. Lang, and B. Guy. 2006. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 24:4914-4926.
52. Schultz-Cherry, S., J. K. Dybing, N. L. Davis, C. Williamson, D. L. Suarez, R. Johnston, and M. L. Perdue. 2000. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278: 55-59.
53. Siegrist, C. A. 2003. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 21:3406-3412.
54. Siegrist, C. A. 2001. Neonatal and early life vaccinology. Vaccine 19:3331-3346.
55. Siegrist, C. A., C. Barrios, X. Martinez, C. Brandt, M. Berney, M. Cordova, J. Kovarik, and P. H. Lambert. 1998. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur. J. Immunol. 28:4138-4148.
56. Simmons, C. P., T. N. Chau, T. T. Thuy, N. M. Tuan, D. M. Hoang, N. T. Thien, B. Lien Le, N. T. Quy, N. T. Hieu, T. T. Hien, C. McElnea, P. Young, S. Whitehead, N. T. Hung, and J. Farrar. 2007. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J. Infect. Dis. 196: 416-424.
57. Thompson, J. M., A. C. Whitmore, J. L. Konopka, M. L. Collier, E. M. B. Richmond, N. L. Davis, H. F. Staats, and R. E. Johnston. 2006. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc. Natl. Acad. Sci. USA 103:3722-3727.
58. Thu, H. M., K. Lowry, T. T. Myint, T. N. Shwe, A. M. Han, K. K. Khin, K. Z. Thant, S. Thein, and J. Aaskov. 2004. Myanmar dengue outbreak associated with displacement of serotypes 2, 3, and 4 by dengue 1. Emerg. Infect. Dis. 10:593-597.
59. Van de Perre, P. 2003. Transfer of antibody via mother's milk. Vaccine 21:3374-3376.
60. van Der Most, R. G., K. Murali-Krishna, R. Ahmed, and J. H. Strauss. 2000. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Virol. 74:8094-8101.
61. Vaughn, D. W., S. Green, S. Kalayanarooj, B. L. Innis, S. Nimmannitya, S. Suntayakorn, T. P. Endy, B. Raengsakulrach, A. L. Rothman, F. A. Ennis. and A. Nisalak. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9.
62. Wang, Y., Z. Xiang, S. Pasquini, and H. C. Ertl. 1997. The use of an El-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus. J. Virol. 71:3677-3683.
63. Watanaveeradej, V., T. P. Endy, R. Samakoses, A. Kerdpanich, S. Simasathien, N. Polprasert, C. Aree, D. W. Vaughn, C. Ho, and A. Nisalak. 2003. Transplacentally transferred maternal-infant antibodies to dengue virus. Am. J. Trop. Med. Hyg. 69:123-128.
64. Wesley, R. D., and K. M. Lager. 2006. Overcoming maternal antibody interference by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of swine influenza virus. Vet. Microbiol. 118:67-75.
65. White, L. J., J.-G. Wang, N. L. Davis, and R. E. Johnston. 2001. Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5′ untranslated region. J. Virol. 75:3706-3718.
66. Whitehead, S. S., J. E. Blaney, A. P. Durbin, and B. R. Murphy. 2007. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5:518-528.
67. WHO. 2002. Dengue and dengue hemorrhagic fever. Fact sheet N. 117. WHO, Geneva, Switzerland.
68. WHO. 1997. Dengue hemorrhagic fever, diagnosis, treatment, prevention and control, 2nd ed. WHO, Geneva, Switzerland.
69. Wilson, J. A., M. Bray, R. Bakken, and M. K. Hart. 2001. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 286:384-390.
70. Witayathawornwong, P. 2001. Dengue hemorrhagic fever in infancy at Petchabun Hospital, Thailand. Southeast Asian J. Trop. Med. Public Health 32: 481-487.
71. Wu, Y., F. Zhang, W. Ma, J. Song, Q. Huang, and H. Zhang. 2004. A plasmid encoding Japanese encephalitis virus PrM and E proteins elicits protective immunity in suckling mice. Microbiol. Immunol. 48:585-590.